key: cord-0888951-h3pz52cy
authors: Khan, Mubarak M.; Parab, Sapna R.; Paranjape, Mandar
title: Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic
date: 2020-06-18
journal: Am J Otolaryngol
DOI: 10.1016/j.amjoto.2020.102618
sha: a22bc8b305be9ebfb75d2e71a23706796143dfa4
doc_id: 888951
cord_uid: h3pz52cy

SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries. AIMS: 1. To propose the use of 0.5% Povidone iodine gargles and nasal drops as prerequisite for office based nose and throat examination and procedures during COVID 19 pandemic. 2. To assess tolerability of 0.5% PVP-I in patients and in healthcare workers. MATERIALS AND METHODS: 0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30 s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted. RESULTS: The patient and health care workers tolerated the 0.5%. No allergy was noted. CONCLUSION: We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE.

SARS-CoV-2 causing the COVID 19 Pandemic is highly homologous with SARS-CoV 7 . Invitro study by Eggers et al 5 on the virucidal activity of PVP-I against MERS-CoV showed that the lowest concentration of PVP-I to be effective was 1% when used for 30 seconds under "dirty" conditions, leading to a reduction of viral activity of ≥99.99%; but not effective at 0·1% 5 . In subsequent in-vitro work by Eggers et al 6 , the lowest concentration tested and effective against coronaviruses, was 0·23%. Kariwa et al showed that in vitro treatment of J o u r n a l P r e -p r o o f 11 In many ophthalmic surgeries, different dilutions of PVP-I are used for avoiding contamination and it is well tolerated. 12 The oropharynx and nasopharynx are the target sites of novel coronavirus with the result that saliva contains a high viral load of COVID 19 with up to 1.2 x 10 8 infective copies/per ml. 13 As an otorhinolaryngologist is closely working in this area, there is a significant risk of exposure during routine office based examinations of Ear, Nose and Throat and many endoscopy procedures. Even a few microliters of saliva contamination of surfaces or instruments may carry many thousands of infectious viral particles. Though asymptomatic, the viral shedding initial phase of COVID 19 is highly infectious. 14 At present there are no universal guidelines either for preoperative testing or for treatment of for COVID 19, and individual hospitals are creating their own protocols of treatment and prophylaxis. Povidone Iodine (PVP-I) has better antiviral activity than other antiseptics such as chlorhexidine 4 and has already been proven to be an effective virucidal in vitro against similar coronaviruses (SARS -CoV and MERS-Cov) 5, 6, 8 although it has not been tested directly with COVID 19.

Hence, we propose the use of 0.5% PVP-I as gargles and nasal drops as a prerequisite for patients attending ENT Out-Patient department and health care workers attending these patients.

All health care workers and patients attending out-patient department for consultations and for ENT endoscopies in the month of May were included in the study. This included patients with no symptoms of COVID-19 having procedures in or around the mouth and nose or procedures that transit those areas and the healthcare professionals carrying out those procedures due to the high incidence of asymptomatic infection.

Exclusion criteria: Patients with history of allergy to PVP-I, all forms of thyroid disease or on radioactive iodine treatment, lithium therapy, known pregnancy, renal failure and dermatitis were excluded from the study. The protocol can be used in children as a single application for Nose, Throat examination after excluding allergy.

The detailed protocol adopted is as follows:

In the hospital setting, we propose application of 0·5% PVP-I solution (0·55 mg/mL available iodine) as gargles onto the oral, oropharyngeal mucosa and as nasal drops onto nasal and nasopharyngeal mucosa of patients with suspected /confirmed COVID-19 and the healthcare workers in close contact with such patients and all routine patients seeking ENT consultation whose COVID 19 status is unknown. Additionally, the application of 0.5% PVP-I can be used for oral surgery, ENT examination and treatment, endo-tracheal intubation, endoscopy and bronchoscopy as a preoperative preparation. Step 1for all patients/ healthcare professionals: The 0·5% PVP-I solution is administered in a dose of 4-5 drops into each nostril 10 minutes prior to examination. For endoscopic procedure, nasal pack with PVP is used and prior nasal douching 2 times prior day

Step 2conscious patients and healthcare professionals: 10 mL of the 0·5% PVP-I solution is then introduced into the oral cavity and used as a mouthwash. Care is taken to ensure the solution is distributed throughout the oral cavity for 30 seconds and then gently gargled or held at the back of the throat for another 30 seconds before spitting out.

Patients hospitalised for confirmed/ suspected COVID 19 and the involved healthcare PVP-I is being extensively used worldwide as a handwashing agent (usually a 7·5% solution containing foaming agents), for pre-procedural skin antisepsis 15 (usually simply as a 10% solution), in ophthalmic surgery 10, 12 (often diluted to 5%) and in oral surgery as 10%. The PVP-I is commercially available in the Far East as a 1% w/v mouthwash for use every 2-4 hours 16 . It is assumed that using a concentration twice as strong as that found to be virucidal in vitro (0·5% versus 0·23% 5,8 ) will be effective to allow for dilution due to saliva as the exact effective concentration of PVP-I in the presence of mucins and saliva is not known.

The intranasal topical application of 0·08% solution of iodine for the treatment of recalcitrant chronic rhinosinusitis has been described by the St. Paul's Sinus Centre team in Vancouver. 17, 18 This application did not cause any significant effect on thyroid function, mucociliary clearance or olfaction. PVP-I use in the nasal cavity to reduce infection or spread is rational for COVID-19 after two recent trials have demonstrated higher viral load there when compared with the oral cavity. 5, 6, 8 PVP-I gargles are very well tolerated as compared to other antiseptic agents gargles 4 . It has been demonstrated in clinically successfully trials that nasal administration and mouthwash reduced pharyngeal bacterial colonization and subsequent reduction in the incidence of nosocomial pneumonia 19 . Povidone-Iodine-Based Solutions are used as preoperative asepsis J o u r n a l P r e -p r o o f preparation in many planned orthopaedic and ophthalmic surgeries for Decolonization of Nasal microbes. 9,10

Considering the antiviral actions of Povidone Iodine at various sites including the extensive use by ophthalmologists for a delicate sensitive special sense organ concerned with vision 10, 11, 12 , there is absolutely no harm in repurposing 0.5% PVP-I to another two special senses' organ for extrapolating its probable antiviral action against SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles. And pre procedure testing for COVID 19 infection, may not be feasible in all patients attending the clinic. Moreover, a false negative test creates a pseudo feeling of security amongst the health care workers. The evidence presented suggests that application of povidone iodine to the nasal and oral mucosa, oropharynx and nasopharynx of patients with COVID-19 may significantly reduce the viral load in these key anatomical areas. This will definitely help to reduce the risk of transmission to health care workers. It also allows a time period to perform procedures at reduced risk. Further reduction of risk of transmission may be achieved by similar application of PVP-I to the HCW providing the care as a form of prophylaxis. We therefore propose that for the duration of the current COVID-19 pandemic.

At low concentrations, staining of teeth is minimal and reversible. 

Review presentation on povidone-iodine antisepsis in the oral cavity

The topical effect of chlorhexidine and povidone-iodine in the repair of oral wounds. A review

In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens

Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)

CoV-2: an emerging coronavirus that causes a global threat

Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology (Basel

Povidone-iodine concentration and dosing in cataract surgery

Povidona yodada. ¿Un nuevo paradigma en el tratamiento de la conjuntivitis adenovírica

Optimizing the antisepsis protocol: Effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0

Consistent detection of 2019 novel coronavirus in saliva

Temporal dynamics in viral shedding and transmissibility of COVID-19. Nature medicine

Preoperative decolonization to reduce infections in urgent lower extremity repairs

The effect of 1% povidone iodine as a pre-procedural mouthrinse in 20 patients with varying degrees of oral hygiene

The efficacy of diluted topical povidone-iodine rinses in the management of recalcitrant chronic rhinosinusitis: a prospective cohort study

Topical Povidone-Iodine as an Adjunctive Treatment for Recalcitrant Chronic Rhinosinusitis

A trial of povidone-iodine (PVP-I) nasal inhalation and gargling to remove potentially pathogenic bacteria colonized in the pharynx

Relevanz einer Jodallergie bei handelsüblichen Polyvidon-Jod-Zubereitungen

Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on iodine absorption and thyroid function

Allergic contact dermatitis from povidone-iodine: A re-evaluation study